Lu Si
North Sichuan Medical University(CN)Central University of Finance and Economics(CN)Soochow University(TW)Peking University(CN)China University of Mining and Technology(CN)Sir Run Run Shaw Hospital(CN)Shanghai Chest Hospital(CN)Peking University Cancer Hospital(CN)Ministry of Education(IR)The People's Hospital of Guangxi Zhuang Autonomous Region(CN)Shandong Provincial Hospital(CN)Ningxia Medical University(CN)Second Hospital of Tianjin Medical University(CN)Zhengzhou Central Hospital(CN)Ministry of Education(ET)Shandong First Medical University(CN)Tianjin Medical University(CN)Southern Medical University(CN)Hubei University(CN)Zhejiang University(CN)Henan University of Economic and Law(CN)University of California, Davis(US)
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses
Most-Cited Works
- → Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification(2011)674 cited
- → Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases(2011)399 cited
- → Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets(2019)326 cited
- → Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma(2020)271 cited
- → Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort(2011)264 cited
- → Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma